Indexes of anticoagulation control and major adverse outcomes in patients with atrial fibrillation: an analysis from the AFFIRM Trial

17 March 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Associate Professor Marco Proietti

University of Milan, Milan (Italy)

8 More presentations in this session

Presentation thumbnail

Quality of Anticoagulation Control and Major Adverse Outcomes in European Patients with Atrial Fibrillation: Analysis from EORP-AF General Long-Term Registry

Associate Professor M. Proietti (Milan, IT)

Abstract Slides

Presentation thumbnail

The influence of NOAC on sudden neurological death

Doctor B. Slavchev (Sofia, BG)

Abstract Slides

Presentation thumbnail

Ischemic stroke in patient with sinus node disease in comparison to atrial fibrillation, bradycardia-tachycardia syndrome and other cardiac conditions: a nationwide cohort-study

Doctor A. Bodin (Chambray Les Tours, FR)

Presentation thumbnail

Morpho-functional analysis of the left atrium appendage for stroke risk assessment in atrial fibrillation

Doctor C. Tomasi (Ravenna, IT)

Presentation thumbnail

Characteristics associated with death in patients with atrial fibrillation initiated on rivaroxaban and followed up for 1 year on treatment - an analysis in the pooled XANTUS data

Professor J. Camm (London, GB)

Access the full session

Session thumbnail

Poster session 3 - Atrial Fibrillation - Stroke Prevention

The Event

EHRA 2019

17 March - 19 March 2019

You may be interested in

Congress Presentation

Device-detected or clinically diagnosed atrial fibrillation: the same decision for oral anticoagulation therapy - pro

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

Oral anticoagulation in subclinical atrial fibrillation: pro

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources